Raising survival rates in Osteosarcoma
Mepact (mifamurtide) L-MTP-PE* is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, used in combination with post-operative multi-agent chemotherapy.
Liposomal muramyl tripeptide phosphatidyl ethanolamine is a synthetic analogue of muramyl dipeptide, the smallest natural immuno-adjuvant from the mycobacterium cell wall.1
The first therapeutic advance in osteosarcoma for more than 20 years2
Mepact has been licensed by the EMA since March 2009 and was shown to significantly improve overall survival in high-grade, non-metastatic osteosarcoma in chemotherapy and radiation therapy-naïve patients.3,4
Mepact showed an increase in patients’
six-year overall survival rates from 70 to 78%
In a large and extensive investigator initiated Phase III study carried out in newly diagnosed osteosarcoma patients, Mepact in combination with chemotherapy significantly improved six-year overall patient survival and reduced the risk of death by almost one third, when compared to chemotherapy along (MAP) (absolute risk reduction 8%, p=0.03).3,4
Mepact Mechanism of Action
A look at how mifamurtide targets micro-metastases and improves survival rates.
Mepact and Me
A person’s journey with osteosarcoma and how Mepact changed her expectations.